Literature DB >> 8666063

Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders.

J Ge1, N M Barnes.   

Abstract

The present studies assessed the levels of [125I][Sar1,ILE8]angiotensin II-labelled angiotensin AT1 and AT2 receptor recognition sites in homogenates of various brain areas (including caudate nucleus, putamen, substantia nigra, hippocampus, frontal cortex, temporal cortex and cerebellum) from patients with clinically diagnosed Parkinson's disease, Huntington's disease and Alzheimer's disease and those from age-, sex- and post-mortem delay-matched neurologically and psychiatrically normal patients. Radiolabelled angiotensin AT1 receptor recognition site levels were significantly decreased by approximately 70%, 70% and 90% in the caudate nucleus, putamen and substantia nigra, respectively, from patients with Parkinson's disease relative to matched controls. Furthermore, radiolabelled angiotensin AT2 receptor levels were decreased by some 60% in the caudate nucleus of patients with Parkinson's disease relative to control patients. In brain tissue homogenates from patients with Huntington's disease, the angiotensin AT1 receptor recognition site levels were decreased by approximately 30% in putamen relative to the control patients whilst angiotensin AT2 receptor levels were increased by some 90% in the caudate nucleus relative to the control patients. In brain tissue homogenates from patients with Alzheimer disease, the angiotensin AT2 receptor recognition site levels were significantly increased by approximately 200% in the temporal cortex relative to the control patients. The present results indicate that the reduction of angiotensin AT1 and/or AT2 receptor recognition site levels in the caudate nucleus, putamen and substantia nigra correlates with the principal neuropathology associated with Parkinson's disease and as such indicates that at least a significant population of angiotensin AT1 and AT2 receptors are located on the human dopaminergic nigrostriatal pathway. In addition, the marked increase in the levels of angiotensin AT2 receptor recognition sites in temporal cortex from patients with Alzheimer's disease correlates with some other markers associated with the renin-angiotensin system previously investigated in tissue from patients with this neurological disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666063     DOI: 10.1016/0014-2999(95)00762-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

Review 1.  Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?

Authors:  Philip Rosenstiel; Stefan Gallinat; Alexander Arlt; Thomas Unger; Jobst Sievers; Ralph Lucius
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Angiotensin II inhibits iron uptake and release in cultured neurons.

Authors:  Yong Liu; Suna Huang; Fang Du; Guang Yang; Li Rong Jiang; Chao Zhang; Zhong-ming Qian
Journal:  Neurochem Res       Date:  2014-03-30       Impact factor: 3.996

3.  Human brain contains a novel non-AT1, non-AT2 binding site for active angiotensin peptides.

Authors:  Vardan T Karamyan; Craig A Stockmeier; Robert C Speth
Journal:  Life Sci       Date:  2008-07-22       Impact factor: 5.037

4.  Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.

Authors:  Vidya Narayanaswami; Sucharita S Somkuwar; David B Horton; Lisa A Cassis; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

5.  The GRK2 Overexpression Is a Primary Hallmark of Mitochondrial Lesions during Early Alzheimer Disease.

Authors:  Mark E Obrenovich; Hector H Palacios; Eldar Gasimov; Jerzy Leszek; Gjumrakch Aliev
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-03-03

Review 6.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

7.  Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions.

Authors:  Mark E Obrenovich; Mark A Smith; Sandra L Siedlak; Shu G Chen; Jack C de la Torre; George Perry; Gjumrakch Aliev
Journal:  Neurotox Res       Date:  2006-08       Impact factor: 3.911

8.  Angiotensin II type 1 receptors may not influence response of spinal autonomic neurons to axonal damage.

Authors:  Hui Tang; Jaroslav Pavel; Juan M Saavedra; Stephen Brimijoin
Journal:  Neurol Res       Date:  2008-05-21       Impact factor: 2.448

9.  Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.

Authors:  Tom N Grammatopoulos; Tiago F Outeiro; Bradley T Hyman; David G Standaert
Journal:  Biochem Biophys Res Commun       Date:  2007-09-21       Impact factor: 3.575

Review 10.  Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation.

Authors:  Mark E Obrenovich; Ludis A Morales; Celia J Cobb; Justin C Shenk; Gina M Méndez; Kathryn Fischbach; Mark A Smith; Eldar K Qasimov; George Perry; Gjumrakch Aliev
Journal:  J Cell Mol Med       Date:  2008-10-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.